Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine

22 Sept 2021

Abstract excerpt

Regulatory agencies across the globe had given emergency use authorization of the highly effective Pfizer-BioNTech COVID-19 messenger RNA (mRNA) vaccine (BNT162b2) in view of the ongoing COVID-19 pandemic. In phase 3 trials, the vaccine, which uses an mRNA platform encoding the spike glycoprotein of SARS-CoV-2, confers 52% protection against COVID-19 12 days following the first dose and 95% protection after the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dermatological and COVID-19 studies
Share to Immunotherapy and Immune Responses
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34611542
DOI: 10.1016/j.jdcr.2021.09.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccinePMID 34611542Read ↗

Flare-up of generalized pustular psoriasis following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: Two cases without mutations of IL36RN and CARD14 genes.Semantic proximity Read ↗

A case series of interesting mucocutaneous presentations in COVID-19 infection or post COVID-19 vaccination confirmed by biopsy and histopathologic assessmentSemantic proximity Read ↗

Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA VaccineSemantic proximity Read ↗

The impact of biologic treatment in psoriasis patients on COVID-19 infection: A single-center retrospective studySemantic proximity Read ↗

Breakthrough Opportunities of Nanotheranostics in Psoriasis: From Pathogenesis to Management StrategySemantic proximity Read ↗

Pityriasis Rosea Shortly After mRNA-1273 COVID-19 VaccinationSemantic proximity Read ↗

Cutaneous Reactions after COVID-19 Vaccines – Analysis of the Clinical and Histological Spectrum – Case Series and Review of the LiteratureSemantic proximity Read ↗

Alopecia universalis after injection of messenger RNA COVID-19 vaccine. A case reportSemantic proximity Read ↗

Rapid Progressive Systemic Sclerosis Following mRNA COVID-19 VaccinationSemantic proximity Read ↗

Cutaneous lymphocytic vasculitis after administration of COVID ‐19 mRNA vaccineSemantic proximity Read ↗

Marked differences in Betapapillomavirus DNA and antibody prevalence between patients with psoriasis and those with atopic dermatitis.Semantic proximity Read ↗

Molecular Characterization of Human Skin Response to Diphencyprone at Peak and Resolution Phases: Therapeutic InsightsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.